Seawolf Therapeutics, a San Diego DNA therapeutics developer, emerged from stealth with $100 million in new backing and a partnership with Sanofi. The startup is focused on delivering engineered DNA without viruses, using its TRIDENT platform built around lipid nanoparticles and an auxiliary component intended to route DNA to the nucleus. Seawolf’s financing was led by Versant Ventures and included participation from MPM BioImpact and Alexandria Venture Investments, with Eli Lilly and CRISPR Therapeutics plus Novartis’ venture arm also joining. In tandem with the launch, Seawolf disclosed a multi-target collaboration and exclusive license deal with Sanofi, initially aimed at bleeding disorders and additional unspecified indications. The company said its approach is designed for redosing, addressing a long-standing challenge in gene delivery where viral vectors can drive host immune responses that limit repeat administration.
Get the Daily Brief